Infection with human herpesvirus 8 and transplant-associated gammopathy

Transplantation. 2004 May 27;77(10):1551-4. doi: 10.1097/01.tp.0000129065.31427.96.

Abstract

Background: The role of human herpesvirus (HHV)-8 in the pathogenesis of multiple myeloma and its pre-malignant state of monoclonal gammopathy is unclear. HHV-8 is transmitted by organ transplantation, representing a unique model with which to investigate primary HHV-8 infection.

Methods: The authors studied the incidence of clonal gammopathy in renal transplant recipients and correlated it with previous and recent HHV-8 infection.

Results: Clonal gammopathy was observed in 31 of 162 (19%) HHV-8-seronegative patients, in 5 of 17 (29%) HHV-8-seropositive patients, and in 9 of 24 (38%) HHV-8 seroconverters within 5 years after transplantation. Gammopathy was often transient, and no progression to myeloma was observed. Two patients with persistent gammopathy developed B-cell lymphoma. In a logistic regression model, HHV-8 serostatus of the graft recipient was significantly associated with subsequent development of gammopathy, with a relative risk (RR) of 1.9 and a 95% confidence interval (CI) of 0.5 to 6.4 for an HHV-8-seropositive recipient and an RR of 2.9 and a 95% CI of 1.01 to 8.0 for seroconverters as compared with baseline (HHV-8 seronegative). Other significant variables were cytomegalovirus (CMV) serostatus and the intensity of immunosuppression (RR of 10.4 and 95% CI of 2.6-41.7 for a CMV-negative recipient with a CMV-positive donor vs. a CMV-negative recipient with a CMV-negative donor and RR of 17.6 and 95% CI of 2.0-150.8 if OKT3 was used vs. no use of antilymphocytic substances).

Conclusions: Transplant recipients with HHV-8 infection are more likely to develop clonal gammopathy. However, this risk is much lower than the risk conferred by CMV infection and antilymphocytic therapy, arguing against a major role of HHV-8 infection in the pathogenesis of clonal plasma cell proliferation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antilymphocyte Serum / adverse effects
  • Cytomegalovirus Infections / complications
  • Cytomegalovirus Infections / epidemiology
  • Cytomegalovirus Infections / etiology
  • Herpesviridae Infections / complications*
  • Herpesviridae Infections / epidemiology
  • Herpesviridae Infections / etiology
  • Herpesvirus 8, Human* / physiology
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Incidence
  • Kidney Transplantation / adverse effects*
  • Logistic Models
  • Muromonab-CD3 / adverse effects
  • Paraproteinemias / complications*
  • Paraproteinemias / epidemiology
  • Paraproteinemias / etiology*
  • Risk
  • Tissue Donors
  • Virus Activation

Substances

  • Antilymphocyte Serum
  • Immunosuppressive Agents
  • Muromonab-CD3